Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERIM: intermittent versus continuous dabrafenib + trametinib in BRAFV600 mutant unresectable or metastatic melanoma
2016-005228-27Phase 2Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in melanoma, sponsored by Cambridge University Hospitals NHS Foundation Trust. Status: unknown.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2016-005228-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005228-27.